Impact of sertraline on weight, waist circumference and glycemic control: A prospective clinical trial on depressive diabetic type 2 patients

Aim: Depression is prevalent in patients with type 2 diabetes. It may have a negative impact on the management of diabetes mellitus and could affect weight. The main aim of the investigation was to evaluate the effect of antidepressant treatment (sertraline) on anthropometric variables and glycemic control in depressed type 2 diabetic patients. Methods: Thirty three type 2 diabetic outpatients depressed received open-label sertraline therapy for up to 12 weeks. Clinical outcome measures included the 17-item Hamilton depression rating. Changes in the anthropometrics variables were evaluated by measuring weight, waist circumference and by calculating body mass index at three, six and 12 weeks of treatment. In addition, fasting, postprandial plasma glucose level, glycosylated hemoglobin-A 1C measures, lipid and renal profile were obtained before and during sertraline therapy. Results: Weight decreased significantly (-2 kg; p = 0.000) and body mass index decreased from 30.41 kg/m(2) to 29.6 kg/m(2) (p = 0.000). Patients lost on average seven centimeters in waist circumference (p = 0.000). We also observed a modest, non-significant reduction in fasting, postprandial and glycosylated hemoglobin. We observed a significant reduction in mean score according to the Hamilton depression scale (p = 0.000) Conclusion: Our study results suggested that sertraline produced a benefic effect on weight, body mass index and waist circumference at 12-week follow up. (C) 2018 Primary Care Diabetes Europe. Published by Elsevier Ltd. All rights reserved.